Horizon Pharma PLC Performance
| HZNPDelisted Stock | USD 100.40 0.13 0.13% |
The company retains a Market Volatility (i.e., Beta) of -0.2, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Horizon Pharma are expected to decrease at a much lower rate. During the bear market, Horizon Pharma is likely to outperform the market. Horizon Pharma PLC right now retains a risk of 0.0%. Please check out Horizon Pharma treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Horizon Pharma will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Horizon Pharma PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Horizon Pharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 1.6 B | |
| Total Cashflows From Investing Activities | -134 M |
Horizon |
Horizon Pharma Relative Risk vs. Return Landscape
If you would invest 10,040 in Horizon Pharma PLC on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Horizon Pharma PLC or generate 0.0% return on investment over 90 days. Horizon Pharma PLC is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Horizon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Horizon Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Horizon Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Horizon Pharma PLC, and traders can use it to determine the average amount a Horizon Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| HZNP |
Based on monthly moving average Horizon Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Horizon Pharma by adding Horizon Pharma to a well-diversified portfolio.
Horizon Pharma Fundamentals Growth
Horizon Stock prices reflect investors' perceptions of the future prospects and financial health of Horizon Pharma, and Horizon Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Horizon Stock performance.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Price To Earning | 32.55 X | |||
| Price To Book | 5.10 X | |||
| Price To Sales | 6.93 X | |||
| Revenue | 3.63 B | |||
| EBITDA | 1.11 B | |||
| Cash And Equivalents | 2.13 B | |||
| Cash Per Share | 9.40 X | |||
| Total Debt | 2.56 B | |||
| Debt To Equity | 0.53 % | |||
| Book Value Per Share | 23.20 X | |||
| Cash Flow From Operations | 1.26 B | |||
| Earnings Per Share | 1.88 X | |||
| Total Asset | 9.11 B | |||
| Retained Earnings | 590.01 M | |||
| Current Asset | 1.11 B | |||
| Current Liabilities | 357.55 M | |||
About Horizon Pharma Performance
Assessing Horizon Pharma's fundamental ratios provides investors with valuable insights into Horizon Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Horizon Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois Chicago, Illinois Lake Forest, Illinois South San Francisco, California Washington, D.C. Gaithersburg, Maryland Rockville, Maryland and Mannheim, Germany. Horizon Therapeutics is traded on NASDAQ Exchange in the United States.Things to note about Horizon Pharma PLC performance evaluation
Checking the ongoing alerts about Horizon Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Horizon Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Horizon Pharma PLC is not yet fully synchronised with the market data | |
| Horizon Pharma PLC has a very high chance of going through financial distress in the upcoming years | |
| Over 99.0% of the company shares are owned by institutional investors |
- Analyzing Horizon Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Horizon Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Horizon Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Horizon Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Horizon Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Horizon Pharma's stock. These opinions can provide insight into Horizon Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |